

Berta MarÃ-a Pascual Sedano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6844791/publications.pdf>

Version: 2024-02-01

87
papers

5,393
citations

94381

37
h-index

85498

71
g-index

93
all docs

93
docs citations

93
times ranked

5751
citing authors

#	ARTICLE	IF	CITATIONS
1	Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. <i>Brain</i> , 2005, 128, 2240-2249.	3.7	963
2	Mania following deep brain stimulation for Parkinson's disease. <i>Neurology</i> , 2002, 59, 1421-1424.	1.5	277
3	Parkinson's disease's cognitive rating scale: A new cognitive scale specific for Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 998-1005.	2.2	264
4	A Randomized Placebo-Controlled Comparative Trial of Gabapentin and Propranolol in Essential Tremor. <i>Archives of Neurology</i> , 1999, 56, 475.	4.9	205
5	Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. <i>Movement Disorders</i> , 2008, 23, 1889-1896.	2.2	190
6	Minor hallucinations occur in drug-naïve Parkinson's disease patients, even from the premotor phase. <i>Movement Disorders</i> , 2016, 31, 45-52.	2.2	167
7	Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two-year follow-up study of previously untreated patients. <i>Movement Disorders</i> , 2000, 15, 613-626.	2.2	148
8	Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. <i>Movement Disorders</i> , 2012, 27, 393-399.	2.2	144
9	Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1154-1161.	2.2	140
10	Dementia Risk in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 359-64.	4.9	125
11	Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 58-64.	1.1	122
12	Cutoff score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1546-1550.	2.2	117
13	Controlled study of decision-making and cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1430-1435.	2.2	116
14	Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson's Disease. <i>PLoS ONE</i> , 2013, 8, e54980.	1.1	112
15	Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: The ANIMO study. <i>Movement Disorders</i> , 2012, 27, 211-218.	2.2	105
16	Transcranial Magnetic Stimulation of the Cerebellum in Essential Tremor. <i>Archives of Neurology</i> , 2002, 59, 413.	4.9	104
17	Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson disease. <i>Journal of Neurology</i> , 2003, 250, 917-923.	1.8	103
18	Bilateral pallidal stimulation for cervical dystonia: Dissociated pain and motor improvement. <i>Neurology</i> , 2000, 55, 1754-1755.	1.5	81

#	ARTICLE	IF	CITATIONS
19	Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 871-876.	1.1	79
20	Semantic Knowledge of Famous People in Mild Cognitive Impairment and Progression to Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 188-195.	0.7	74
21	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 151-157.	1.1	71
22	Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2785-2791.	2.2	70
23	Measuring functional impact of cognitive impairment: Validation of the Parkinson's Disease Cognitive Functional Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 812-817.	1.1	69
24	Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study. <i>Movement Disorders</i> , 2007, 22, 62-67.	2.2	67
25	COPPADIS-2015 (COhort of Patients with PARKinson's Disease in Spain, 2015), a global "clinical evaluations, serum biomarkers, genetic studies and neuroimaging" prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. <i>BMC Neurology</i> , 2016, 16, 26.	0.8	66
26	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 460-468.	2.2	66
27	Prospective Study of New-Onset Seizures in Patients With Human Immunodeficiency Virus Infection. <i>Archives of Neurology</i> , 1999, 56, 609.	4.9	61
28	Parkinson's disease's cognitive rating scale: Psychometrics for mild cognitive impairment. <i>Movement Disorders</i> , 2013, 28, 1376-1383.	2.2	58
29	Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 78-86.	2.2	58
30	Routine Neurophysiologic Tremor Analysis as a Diagnostic Tool for Essential Tremor: A Prospective Study. <i>Journal of Clinical Neurophysiology</i> , 2004, 21, 446-450.	0.9	56
31	Apathy in Parkinson's Disease: Neurophysiological Evidence of Impaired Incentive Processing. <i>Journal of Neuroscience</i> , 2014, 34, 5918-5926.	1.7	55
32	Gaba and serotonin molecular neuroimaging in essential tremor: A clinical correlation study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 876-880.	1.1	50
33	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	2.2	47
34	Tremor dominant parkinsonism: Clinical description and <i>LRRK2</i> mutation screening. <i>Movement Disorders</i> , 2008, 23, 518-523.	2.2	46
35	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease. <i>Human Molecular Genetics</i> , 2015, 24, 2023-2034.	1.4	45
36	Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders. <i>Movement Disorders</i> , 2001, 16, 1098-1104.	2.2	42

#	ARTICLE	IF	CITATIONS
37	Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. European Journal of Neurology, 2008, 15, 953-959.	1.7	42
38	A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Movement Disorders, 2008, 23, 443-448.	2.2	41
39	Levodopa and executive performance in Parkinson's disease: A randomized study. Journal of the International Neuropsychological Society, 2008, 14, 832-841.	1.2	41
40	A Double-Blind Crossover, Placebo-Controlled Study of the Adenosine A2A Antagonist Theophylline in Parkinson's Disease. Clinical Neuropharmacology, 2002, 25, 25-31.	0.2	39
41	A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment. Human Brain Mapping, 2019, 40, 3233-3242.	1.9	38
42	Transcranial Direct Current Stimulation of the Cerebellum in Essential Tremor: A Controlled Study. Brain Stimulation, 2014, 7, 491-492.	0.7	33
43	Facial Emotion Recognition Impairment in Patients with Parkinson's Disease and Isolated Apathy. Parkinson's Disease, 2010, 2010, 1-5.	0.6	32
44	COPPADIS 2015 Cohort of Patients with Parkinson's Disease in Tj ETQq0 0 0 rgBT /Overlock 1000 subjects included. Results from the baseline evaluation. European Journal of Neurology, 2019, 26, 1399-1407.	1.7	32
45	PDD-Short Screen: A brief cognitive test for screening dementia in Parkinson's disease. Movement Disorders, 2010, 25, 440-446.	2.2	31
46	Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism and Related Disorders, 2008, 14, 443-445.	1.1	29
47	Diagnostic potential of acoustic startle reflex, acoustic blink reflex, and electro-oculography in progressive supranuclear palsy: A prospective study. Movement Disorders, 2003, 18, 1273-1279.	2.2	27
48	Abnormalities of the acoustic startle reflex and reaction time in Gilles de la Tourette syndrome. Clinical Neurophysiology, 2000, 111, 1366-1371.	0.7	25
49	Spectroscopic Changes Associated with Mild Cognitive Impairment and Dementia in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2012, 34, 312-318.	0.7	24
50	Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity. Frontiers in Psychiatry, 2018, 9, 465.	1.3	24
51	Tremor Types in Parkinson Disease: A Descriptive Study Using a New Classification. Parkinson's Disease, 2018, 2018, 1-5.	0.6	22
52	Using the WHOQOL-DIS to Measure Quality of Life in Persons with Physical Disabilities Caused by Neurodegenerative Disorders. Neurodegenerative Diseases, 2011, 8, 178-186.	0.8	21
53	Effect of amantadine in essential tremor: A randomized, placebo-controlled trial. Movement Disorders, 2006, 21, 441-445.	2.2	19
54	Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: a prospective observational study. Journal of Translational Medicine, 2017, 15, 43.	1.8	19

#	ARTICLE	IF	CITATIONS
55	Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients. <i>Movement Disorders</i> , 2017, 32, 165-169.	2.2	19
56	Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients. <i>Drugs and Aging</i> , 2015, 32, 401-407.	1.3	18
57	Predictors of clinically significant quality of life impairment in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 118.	2.5	17
58	In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 68-75.	1.1	16
59	Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1611-1620.	1.5	15
60	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 175-180.	1.1	13
61	Perampanel, a new hope for Essential tremor: An open label trial. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 171-172.	1.1	13
62	The impact of freezing of gait on functional dependency in Parkinson's disease with regard to motor phenotype. <i>Neurological Sciences</i> , 2020, 41, 2883-2892.	0.9	13
63	Severity stages in essential tremor: a long-term retrospective study using the glass scale. <i>Tremor and Other Hyperkinetic Movements</i> , 2015, 5, 299.	1.1	13
64	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120148.	0.3	13
65	Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. <i>Journal of Neurology</i> , 2021, 268, 3400-3408.	1.8	12
66	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2019, 126, 1599-1608.	1.4	11
67	Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117109.	0.3	11
68	Motor Circuitry Re-organization After Pallidotomy in Parkinson Disease. <i>Journal of Clinical Neurophysiology</i> , 2002, 19, 553-561.	0.9	10
69	Depression is Associated with Impulse-compulsive Behaviors in Parkinson's disease. <i>Journal of Affective Disorders</i> , 2021, 280, 77-89.	2.0	9
70	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease. <i>BMC Neurology</i> , 2021, 21, 477.	0.8	7
71	Impulse control disorders and dopaminergic treatments in Parkinson's disease. <i>Revue Neurologique</i> , 2011, 167, 827-832.	0.6	6
72	Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort. <i>Scientific Reports</i> , 2020, 10, 16893.	1.6	6

#	ARTICLE	IF	CITATIONS
73	The Free and Cued Selective Reminding Test in Parkinson's Disease Mild Cognitive Impairment: Discriminative Accuracy and Neural Correlates. <i>Frontiers in Neurology</i> , 2020, 11, 240.	1.1	6
74	Measuring impulsivity in Parkinson's disease: a correlational and structural neuroimaging study using different tests. <i>European Journal of Neurology</i> , 2020, 27, 1478-1486.	1.7	6
75	Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 63-68.	1.1	6
76	Lacosamide, another therapeutic failure in essential tremor: An open-label trial. <i>Movement Disorders</i> , 2011, 26, 183-184.	2.2	5
77	Preservation of brain metabolism in recently diagnosed Parkinson's impulse control disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2165-2174.	3.3	5
78	A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	5
79	Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson's disease mild cognitive impairment. <i>Brain Imaging and Behavior</i> , 2022, 16, 761-772.	1.1	4
80	Isolated Propriospinal Myoclonus as a Presentation of Cervical Myelopathy. <i>Tremor and Other Hyperkinetic Movements</i> , 2018, 8, 598.	1.1	4
81	Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa. <i>Journal of Neurology</i> , 2020, 267, 3400-3410.	1.8	3
82	Isolated Propriospinal Myoclonus as a Presentation of Cervical Myelopathy. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 8, 598.	1.1	3
83	Horner's syndrome due to giant cell arteritis. <i>Neuro-Ophthalmology</i> , 1998, 20, 75-77.	0.4	2
84	Progressive Posterior Cerebral Artery Infarction Mimicking Middle Cerebral Artery Infarction with Transtentorial Herniation. <i>Cerebrovascular Diseases</i> , 1996, 6, 251-253.	0.8	1
85	Pro-dromic tremor: Prevalence and clinical correlates. <i>Movement Disorders</i> , 2007, 22, 1203-1204.	2.2	1
86	Manejo de la enfermedad de Parkinson y otros trastornos del movimiento en mujeres en edad fértil: Parte 1. <i>Neurología</i> , 2021, 36, 149-158.	0.3	1
87	Manejo de la enfermedad de Parkinson y otros trastornos del movimiento en mujeres en edad fértil: parte 2. <i>Neurología</i> , 2021, 36, 159-168.	0.3	1